Submissions

The following are publicly available submissions to public consultations made by Asthma Australia since its formation as a national body in 2018.

2022
2021
2020

Regional climate change adaptation Strategy for Greater Melbourne: Melbourne’s Climate Journey Discussion Paper, Department of Environment, Land, Water and Planning, December 2020 (VIC)

Senate Select Committee on Tobacco Harm Reduction, November 2020 (Federal)

Consultation Paper: Development of the National Preventive Health Strategy, Department of Health, September 2020 (Federal)

Inquiry into the Queensland Government’s health response to COVID-19, Health, Communities, Disability Services and Domestic and Family Violence Prevention Committee, July 2020 (QLD)

Royal Commission into National Natural Disaster Arrangements, June 2020 (Federal)

Lessons to be learned in relation to the Australian bushfire season 2019-2020, Senate Standing Committees on Finance and Public Administration, May 2020 (Federal)

Inquiry into the Australian Government’s response to COVID-19, Senate Select Committee on COVID-19, May 2020 (Federal)

Inquiry into the health impacts of exposure to poor levels of air quality resulting from bushfires and drought, Legislative Council Portfolio Committee No. 2 – Health, May 2020 (NSW)
2019

Inquiry into allergies and anaphylaxis, Standing Committee on Health, Aged Care and Sport, November 2019 (Federal)

Review of the National Environment Protection Measure, Ambient Air Quality (AAQ) standards, National Environment Protection Council Department of the Environment and Energy, August 2019 (Federal)
2018

Select Committee on Health Services in South Australia, Legislative Council of South Australia, February 2018 (SA)

Pharmaceutical Benefits Advisory Council

Asthma Australia has made submissions to PBAC regarding the following medicines:

2022

Dupixent

Fostair 200

Tezspire

Trimbow
2021

Trelegy

Xolair
2020

Atectura

Dupixent

Enerzair

Fostair

Spiriva Respimat
2019

Budesonide with Formoterol

Fluticasone Furoate

Salbutamol

Symbicort
2018

Benralizumab

Tiotropium

Therapeutic Goods Administration

Asthma Australia has made submissions to the TGA regarding the following consultations

2022

Down scheduling inhaled budesonide
2021

Standard for vaporiser nicotine (TGO 110)
2020

Interim decision to amend the Poisons Standard (nicotine)
2019

Increased online access to ingredient information
2018

Management and communication of medicines shortages

Submissions

Submissions

Submissions

Pharmaceutical Benefits Advisory Council

Therapeutic Goods Administration

Jump to: